New H1-receptor antagonists: clinical pharmacology

Authors

  • F. ESTELLE R. SIMONS

    Corresponding author
    1. Section of Allergy & Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, Canada
    Search for more papers by this author

Dr F. E. R. Simons, Children's Hospital of Winnipeg. 840 Sherbrook Street, Winnipeg, Manitoba, Canada, R3A 1SI.

Summary

The non-sedating, second-generation H1-receptor antagonists such as terfenadine, astemizole, loratadine and cetirizine differ considerably from each other in their pharmacokinetics and pharmacodynamics. They are generally well absorbed when administered orally. They have extremely variable serum elimination half-life values. The maximum antihistaminic effect of these medications occurs several hours later than peak serum concentrations do. The duration of the antihistaminic effect is much longer than would be predicted from the serum elimination half-life values. The relative incidence of anticholinergic and central nervous system adverse effects caused by these medications is similar to that produced by placebo. The introduction of the second-generation H1-receptor antagonists represents a major advance in symptomatic therapy of allergic disorders such as allergic rhinitis and urticaria.

Ancillary